If you developed tardive dyskinesia after taking Reglan (metoclopramide), you may be eligible to file a lawsuit in Georgia. The FDA requires a black box warning about this risk, especially with long-term use. Consult a qualified Georgia attorney to discuss your case and legal options.
If you or a loved one has taken Reglan for an extended period, you may be concerned about the risk of tardive dyskinesia—a movement disorder that can persist after stopping the medication. The medical community has long studied the relationship between drug exposure and neurological side effects, and recent research from Georgia is shedding new light on which patients may need closer monitoring. This page reviews the key risk factors and what the latest findings mean for patient care.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed to treat nausea, vomiting, and gastroparesis (https://pubmed.ncbi.nlm.nih.gov/34712535/). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, highlighting that the risk of developing TD increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning underscores the importance of using Reglan for the shortest possible time and reassessing the need for continued therapy periodically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD can vary widely, from mild, subtle movements to severe, disabling dyskinesias that interfere with daily activities. Diagnosis typically involves a thorough neurological examination and a detailed history of medication exposure, as TD may be masked by ongoing use of metoclopramide (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In some cases, TD can develop after even a single dose of metoclopramide, particularly in patients with underlying risk factors such as advanced age, female sex, or a history of extrapyramidal symptoms (https://pubmed.ncbi.nlm.nih.gov/34712535/). The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the brain, which can lead to supersensitivity of these receptors and subsequent abnormal involuntary movements (https://pubmed.ncbi.nlm.nih.gov/34712535/).
The adequacy of warnings regarding Reglan and TD is a critical issue. The FDA-mandated boxed warning clearly states that Reglan can cause TD and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also advises that Reglan is contraindicated in patients with a history of TD and that treatment should be immediately discontinued if signs or symptoms of TD appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may not have received adequate information about the risks, leading to prolonged use and subsequent harm. In Georgia, as in other states, patients who develop TD after using Reglan may pursue legal claims based on failure to warn or inadequate risk communication (https://pubmed.ncbi.nlm.nih.gov/31356297/). Settlement-related considerations for affected patients in Georgia involve several factors. First, the timeline between exposure to Reglan and the development of TD is variable; while some patients develop symptoms after months or years of use, others may experience onset after short-term exposure (https://pubmed.ncbi.nlm.nih.gov/34712535/). Second, the severity and permanence of TD symptoms can significantly impact quality of life, influencing the potential value of a settlement. Third, evidence of inadequate warnings—such as a physician failing to inform the patient about TD risk or a pharmacy not providing the boxed warning—can strengthen a claim (https://pubmed.ncbi.nlm.nih.gov/31356297/). In Georgia, patients may need to demonstrate that the prescribing healthcare provider or the manufacturer failed to meet the standard of care in communicating risks. The risk of TD is not limited to long-term use; even short courses of Reglan can trigger the condition in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA recommends that for patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is essential (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with gastroesophageal reflux, the maximum treatment duration is also 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these guidelines, some patients may be prescribed Reglan for extended periods without adequate monitoring, increasing their risk of TD. In summary, Reglan use carries a well-documented risk of tardive dyskinesia, a potentially irreversible movement disorder. The FDA boxed warning emphasizes the need for short-term use and careful monitoring. Patients in Georgia who develop TD after Reglan exposure may have legal recourse if they can demonstrate that warnings were inadequate or that the medication was used beyond recommended durations. The timeline between exposure and harm can vary, and settlement considerations depend on symptom severity, duration of use, and the adequacy of risk communication.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. It is linked to tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary movements. The FDA has issued a boxed warning about this risk, which increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Georgia patients who develop TD after Reglan use may pursue legal claims based on failure to warn or inadequate risk communication. They need to demonstrate that the prescribing healthcare provider or manufacturer failed to meet the standard of care in communicating risks. Settlement considerations include symptom severity, duration of use, and evidence of inadequate warnings (https://pubmed.ncbi.nlm.nih.gov/31356297/).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.